Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Veruno (NO), Italy.
Int J Cardiol. 2013 Oct 9;168(4):3419-23. doi: 10.1016/j.ijcard.2013.04.184. Epub 2013 May 16.
Both heart failure (HF) treatment and management may distort or enhance the predictive accuracy of low peak oxygen consumption (pVO2≤10 ml/kg/min), blurring the identification of specific patients in whom heart transplantation (HT) could make a clinical difference. The aim of this study was to re-evaluate the prognostic significance of pVO2≤10 ml/kg/min in systolic HF in light of changes in medical treatment and management.
Two-year outcomes were compared across the "millennium dawn" (MD) between two HF cohorts with pVO2≤10 ml/kg/min and gas exchange ratio>1.10: 116 patients were recorded between 1994 and 1999 (pre-MD: mean pVO2 8.6±1.1 ml/kg/min) and 90 between 2001 and 2008 (post-MD: mean pVO2 8.8±1.0 ml/kg/min). Cardiac-related death was considered an event and event censoring was interrupted at 24 months for surviving patients.
Patients across the MD had the same age, NYHA class, left ventricular ejection fraction and pVO2 (pre-MD: mean pVO2 8.6±1.1; post-MD: mean pVO2 8.8±1.0 ml/kg/min: NS). Seventy-one patients (34%) died: 51 (44%) in the pre-MD and 20 (22%) in the post-MD group (p<0.01). The post-MD group showed a better mean 1-year (83% vs. 68%; χ(2)=5.17, p=0.0229) and 2-year survival (77% vs. 56%; χ(2)=8.87, p=0.0029) compared to pre-MD patients.
Two-year outcome of HF patients with pVO2≤10 ml/kg/min has significantly improved in the post-MD era, suggesting the HT indication should not rely on a single CPET parameter, rather on a multifactorial clinical approach.
心力衰竭(HF)的治疗和管理都可能会扭曲或增强低峰值摄氧量(pVO2≤10ml/kg/min)的预测准确性,使得心脏移植(HT)能够产生临床差异的特定患者的识别变得模糊。本研究的目的是根据治疗和管理的变化,重新评估收缩性心力衰竭患者中 pVO2≤10ml/kg/min 的预后意义。
在两个 pVO2≤10ml/kg/min 且气体交换比>1.10:1 的 HF 队列的“千禧年曙光”(MD)期间,比较了两年的结局:1994 年至 1999 年期间记录了 116 例患者(MD 前:平均 pVO2 为 8.6±1.1ml/kg/min),2001 年至 2008 年期间记录了 90 例患者(MD 后:平均 pVO2 为 8.8±1.0ml/kg/min)。心脏相关死亡被视为事件,对于存活患者,事件截止时间为 24 个月。
MD 期间的患者具有相同的年龄、NYHA 分级、左心室射血分数和 pVO2(MD 前:平均 pVO2 为 8.6±1.1ml/kg/min;MD 后:平均 pVO2 为 8.8±1.0ml/kg/min:无统计学意义)。71 例患者(34%)死亡:MD 前组 51 例(44%),MD 后组 20 例(22%)(p<0.01)。与 MD 前组相比,MD 后组患者的平均 1 年(83% vs. 68%;χ(2)=5.17,p=0.0229)和 2 年生存率(77% vs. 56%;χ(2)=8.87,p=0.0029)均有显著改善。
在 MD 后时代,pVO2≤10ml/kg/min 的 HF 患者的两年结局有了显著改善,这表明 HT 适应证不应依赖于单一 CPET 参数,而应采用多因素临床方法。